# 嘉義縣衛生局 函

地址:61249嘉義縣太保市祥和二路東段3

號

承辦人:陳惠貞

電話: 05-3620600-229 傳真: 05-3620601

電子信箱: jone@cyshb. gov. tw

60045

嘉義市仁爱路347號5樓之8

受文者: 嘉義縣藥師公會

發文日期:中華民國106年8月28日

發文字號: 嘉衛藥食字第1060023277號

的藥物**等**食品管理和

速別:普通件

密等及解密條件或保密期限:

附件: 見主旨



主旨:檢送案內所陳偽藥「Avastin(主成分bevacizumab)400mg tablets」及「Sutent(主成分sunitinib malate)12.5mg tablets」標示由AstraZeneca公司製造之警訊相關資料1份, 發現在烏干達流通,為維護國民之健康與安全,惠請貴會轉 知所屬會員知悉,請查照。

## 說明:

- 一、依據衛生福利部食品藥物管理署106年8月24日FDA企字第 1061203046號函辦理。
- 二、經查旨揭2項主成分,本署核准之藥品許可證資料簡述如下:
  - (一)Avastin(bevacizumab)25mg/ml Injection(衛署菌疫輸字第000807號),製造廠為ROCHE公司。
  - (二)Sutent(sunitinib malate)12.5mg Capsules(衛署藥輸字 第024593號),製造廠為PFIZER公司。
- 三、副本抄送轄區各鄉鎮市衛生所,請將該產品於市面可能販售及網路刊售之情事列入稽查工作重點。

正本: 嘉義縣藥師公會、嘉義縣藥劑生公會、嘉義縣西藥商業同業公會、社團法人嘉義縣醫師公會

副本:嘉義縣大林鎮衛生所、嘉義縣溪口鄉衛生所、嘉義縣新港鄉衛生所、嘉義縣阿里 山鄉衛生所、嘉義縣大埔鄉衛生所、嘉義縣番路鄉衛生所、嘉義縣梅山鄉衛生所 、嘉義縣竹崎鄉衛生所、嘉義縣中埔鄉衛生所、嘉義縣水上鄉衛生所、嘉義縣義 竹鄉衛生所、嘉義縣東石鄉衛生所、嘉義縣六腳鄉衛生所、本局聯合稽查隊、本





線

依分層負責規定授權主管科長決行





20, AVENUE APPIA - CH-1211 GENEVA 27 - SWITZERLAND - TEL CENTRAL +41 22 791 2111 - FAX CENTRAL +41 22 791 3111 - WWW.WHO.INT

Ref. RHT/SAV/Alert 3.2017

18 August 2017

#### Medical Product Alert No 3/2017

# Falsified Avastin (bevacizumab) and Sutent (sunitinib malate) circulating in East Africa

This Medical Product Alert relates to two falsified medicines discovered by the National Drug Authority, Uganda and reported to WHO.

In July 2017 falsified versions of Avastin (bevacizumab) and Sutent (sunitinib malate) were seized by the National Drug Authority, Uganda. Both products were being distributed in the vicinity of various cancer treatment centres in Kampala, Uganda.

The genuine manufacturers of both products have confirmed that they did not manufacture these products.

Details and photographs of both falsified products are shown below:

1: Avastin (Bevacizumab) 400 mg	
Product Name	Avastin
Batch Number	NC 1060
Expiry Date	02 - 2019
Stated Active Pharmaceutical ingredient	Bevacizumab
Stated Manufacturer	Astrazeneca/AstraZenaca


Avastin is the trade name of a medicine manufactured by Roche/Genentech for the treatment of various cancers. It is not manufactured by AstraZeneca as stated on the falsified versions.

This falsified version of Avastin is being presented in plastic bottles containing blue/grey tablets. The genuine version of Avastin is supplied only as an injection for intravenous use.

Fig 1. Falsified Avastin



Fig 2. Falsified Avastin



2: Sutent (sunitinib malate) 12.5 mg	
Product Name	Sutent
Batch Number	NC 2001
Expiry Date	02 - 2019
Stated Active Pharmaceutical Ingredient	sunitinib malate
Stated Manufacturer	Astrazeneca/AstraZenaca

Sutent is the trade name of a medicine for the treatment of pancreatic cancer manufactured by Pfizer. It is not manufactured by AstraZeneca as shown on the falsified versions.

This falsified version of Sutent is presented in plastic bottles containing blue/grey tablets. Genuine Sutent is only available as gelatin capsules.

Fig 3. Falsified Sutent



Fig 4. Falsified Sutent



WHO requests increased vigilance within the supply chains of countries likely to be affected by these falsified products. Increased vigilance should include hospitals, clinics, health centres, wholesalers, distributors, pharmacies and any other suppliers of medical products.

If you are in possession of these products, please do not use them. If you have taken this falsified product, or if you suffer an adverse event having taken these products, please seek immediate advice from a qualified healthcare professional, and report the incident to your local Ministry of Health/National Medicines Regulatory Authorities/National Pharmacovigilance Centre.

It is necessary to ensure that all medical products are obtained from authentic and reliable sources. Their authenticity and condition should be carefully checked. Seek advice from a healthcare professional if there is any doubt.

National health authorities are asked to immediately notify WHO if these falsified products are discovered in their country. If you have any information concerning the manufacture, distribution, or supply of these products, please contact rapidalert@who.int

### WHO Global Surveillance and Monitoring System on Substandard and Falsified Medical Products

For further information, please visit our website: http://www.who.int/medicines/regulation/ssffc/en/
To sign up for WHO Medical Product Alerts, please visit: http://www.who.int/about/licensing/rss/en/